Cord Blood Registry (CBR) by Generate Life Sciences and NantKwest (NK +6.7%) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells.
CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells
Patient trials expected to begin in the fall, and both companies anticipate an FDA-approved treatment to be in the market for use in Covid-19 patients by early 2021.
